Interleukin-3 receptor signaling is a driver of myeloid leukaemia and a significant therapeutic target

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1103244

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. There are many types of AML, but overall, less than half of those with AML are cured. This project evaluates how certain molecules on the surfaces of leukaemic cells keep those cells alive and growing. We are also testing new ways to block these molecules and so provide new therapies for this cancer.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $601,966.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Cell Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer biology | cancer research | interleukins (IL) | myeloid leukaemia | receptor signalling

Related Links